Overview

NAC to Prevent Cisplatin-induced Hearing Loss

Status:
Active, not recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

Cisplatin is a key chemotherapy agent for the treatment of multiple childhood cancers but causes permanent hearing loss. This study investigates the drug N-acetylcysteine (NAC) to determine the dose necessary to protect hearing and also how well tolerated NAC is when combined with chemotherapy.

Phase:

Phase 1

Details

Lead Sponsor:

Children's Hospital Los Angeles

Treatments:

Acetylcysteine
Cisplatin
N-monoacetylcystine